3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Hepatoblastoma
2
Glioblastoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Ototoxicity
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Dexamethasone
238
Lenalidomide
145
daratumumab
123
Bortezomib
101
pomalidomide
86
Calcium Dobesilate
76
carfilzomib
74
Cyclophosphamide
70
Specimen Handling
42
isatuximab
40
Biopsy
40
fludarabine
36
belantamab mafodotin
36
Magnetic Resonance Spectroscopy
35
talquetamab
29
dexamethasone acetate
27
dexamethasone 21-phosphate
27
Melphalan
27
auricularum
26
iberdomide
25
ixazomib
22
fludarabine phosphate
22
selinexor
21
elotuzumab
21
Whole-Body Irradiation
14
X-Rays
13
tocilizumab
12
venetoclax
11
Mycophenolic Acid
10
trametinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
Vorinostat
×
1 year
×
Clear all
NCT01502085
2026-04-03
RZD
Hackensack Meridian Health
Phase 1/2
Completed
25 enrolled
5 charts
NCT01297764
2026-03-23
QUAD
Hackensack Meridian Health
Phase 1/2
Active not recruiting
17 enrolled